Skip to main content
SpringerLink
Log in

Individualisierte Therapie der Osteoporose

Individualized treatment of osteoporosis

  • Schwerpunkt: Metabolische Knochen- und Gelenkerkrankungen
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Osteoporose ist eine systemische Skeletterkrankung, die insbesondere im höheren Lebensalter auftritt. In dieser Lebensphase stellt sie die häufigste Knochenerkrankung dar. Neue Medikamente haben das Therapiespektrum in den letzten Jahren erweitert, sodass eine personalisierte Therapie zunehmend in den Fokus rückt. Von entscheidender Bedeutung ist dabei eine Abwägung von Nutzen und Risiken der einzelnen Medikation, die den individuellen Gegebenheiten Rechnung trägt. Wichtige Gesichtspunkte sind die Osteoporoseform (primär/sekundär), bestehende Komorbiditäten, der Schweregrad der Erkrankung, Geschlecht, Alter und das Nebenwirkungsprofil der infrage kommenden Substanzen.

Abstract

Osteoporosis is the most common clinical disorder of bone metabolism. Treatment decisions should be made on an individual basis, taking into consideration the relative benefits and risks in different patient populations. Drug selection should be based on the form (primary/secondary) and severity of osteoporosis, age, sex, the specific contraindications and precautions for using the various available medications, and existing comorbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abdelazim IA, Abdelrazak KM, Al-Kadi M, Yehia AH, Nusair BM, Faza MA (2014) Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis. Arch Osteoporos 9:189

    Article  PubMed  Google Scholar 

  2. Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM (2016) Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. Osteoporos Int : (Epub ahead of print)

  3. Beck TJ, Fuerst T, Gaither KW, Sutradhar S, Levine AB, Hines T, Yu CR, Williams R, Mirkin S, Chines AA (2015) The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis. Bone 77:115–119

    Article  CAS  PubMed  Google Scholar 

  4. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  CAS  PubMed  Google Scholar 

  5. Black DM, Rosen CJ (2016) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 374:254–262

    Article  PubMed  Google Scholar 

  6. Chapurlat RD (2015) Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women. Ther Adv Musculoskelet Dis 7:103–109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen LX, Zhou ZR, Li YL, Ning GZ, Zhang TS, Zhang D, Feng SQ (2015) Comparison of bone mineral density in lumbar spine and fracture rate among eight drugs in treatments of osteoporosis in men: A network meta-analysis. PLoS ONE 10:e0128032

    Article  PubMed  PubMed Central  Google Scholar 

  8. Cianferotti L, D’Asta F, Brandi ML (2013) A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis 5:127–139

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Collinge C, Favela J (2016) Use of teriparatide in osteporotic fracture patients. Injury 47(Suppl1):S36–S38

    Article  PubMed  Google Scholar 

  10. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  CAS  PubMed  Google Scholar 

  11. Dachverband Osteologie e. V. Prophylaxe, Diagnostik und Therapie der Osteoporose bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen (DVO- Leitlinie 2014.)

  12. Ebina K, Hashimoto J, Kashii M, Hirao M, Kaneshiro S, Noguchi T, Tsukamoto Y, Yoshikawa H (2016) The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab : (Epub ahead of print)

  13. Eriksen EF, Diez-Pérez A, Boonen S (2014) Update on long-term treatment with bisphoshponates for postmenopausal osteoporosis: a systematic review. Bone 58:126–135

    Article  CAS  PubMed  Google Scholar 

  14. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3‑year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645

    Article  CAS  PubMed  Google Scholar 

  15. European Prospective Osteoporosis Study (EPOS) Group, Felsenberg D, Silman AJ, Lunt M, Armbrecht G, Ismail AA, Finn JD, Cockerill WC, Banzer D, Benevolenskaya LI, Bhalla A, Bruges-Armas J, Cannata JB, Cooper C, Dequeker J, Eastell R, Felsch B, Gowin W, Havelka S, Hoszowski K, Jajic I, Janott J, Johnell O, Kanis JA, Kragl G, Lopes-Vaz A, Lorenc R, Lyritis G, Masaryk P, Matthis C, Miazgowski T, Parisi G, Pols HA, Poor G, Raspe HH, Reid DM, Reisinger W, Schedit-Nave C, Stepan JJ, Todd CJ, Weber K, Woolf AD, Yershova OB, Reeve J, O’Neill TW (2002) Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17:716–724

    Article  Google Scholar 

  16. Geusens P (2015) New insights into treatment of osteoporosis in postmenopausal women. RMD Open 1:e000051

    Article  PubMed  PubMed Central  Google Scholar 

  17. Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM (2015) Efficacy and safety of single-dose Zoledronic acid for osteoporosis in frail elderly women: A randomized clinical trial. JAMA 175:913–921

    Google Scholar 

  18. Hadji P, Klein S, Gothe H, Häussler B, Kless T, Schmidt T, Steinle T, Verheyen F, Linder R (2013) Epidemiologie der Osteoporose-Bone Evaluation Study: Eine Analyse von Krankenkassen-Routinedaten. Dtsch Arztebl Int 110:52–57

    PubMed  PubMed Central  Google Scholar 

  19. Hegde V, Jo JE, Andreopoulou P, Lane JM (2015) Effect of osteoporosis medications on fracture healing. Osteoporos Int 27:861

    Article  PubMed  Google Scholar 

  20. Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. Printed by the University of Sheffield. World Health Organization: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843, Geneva: WHO 1994

  21. Kates SL, Ackert-Bicknell CL (2016) How do bisphosphonates affect fracture healing? Injury 47(Suppl 1):S65–S68

    Article  PubMed  Google Scholar 

  22. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443

    Article  CAS  PubMed  Google Scholar 

  23. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420

  24. Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 20:1663–1673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161–3169

    Article  CAS  PubMed  Google Scholar 

  26. Real J, Galindo G, Galván L, Lafarga MA, Rodrigo MD, Ortega M (2015) Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study. PLoS ONE 10:e0118178

    Article  PubMed  PubMed Central  Google Scholar 

  27. Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48–54

    Article  CAS  PubMed  Google Scholar 

  28. Scheidt-Nave C, Banzer D, Abendroth K. Schlussbericht (1997) Multizentrische Studie zu Verteilung, Determination und prädiktivem Wert der Knochendichte in der deutschen Bevölkerung. Förderprojekt des Bundesministeriums für Forschung und Technologie. Förderkennzeichen 01KM 9304/0;1–45

  29. Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K (2014) Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2‑year open-label study. Osteoporos Int 25:1945–1951

    Article  CAS  PubMed  Google Scholar 

  30. Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565

    Article  CAS  PubMed  Google Scholar 

  31. Zhang L, Pang Y, Shi Y, Xu M, Xu X, Zhang J, Ji L, Zhao D (2015) Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Menopause 22:1021–1025

    Article  PubMed  Google Scholar 

  32. Harbeck B, Lehnert H (2015) Personalisierte Osteoporosetherapie. Dtsch Med Wochenschr 140:1672–1677

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Universität zu Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland

    B. Harbeck

  2. Präsidium, Universität zu Lübeck, Lübeck, Deutschland

    H. Lehnert

Authors
  1. B. Harbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Lehnert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Harbeck.

Ethics declarations

Interessenkonflikt

B. Harbeck und H. Lehnert geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

H. Lehnert, Lübeck

M. Reincke, München

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harbeck, B., Lehnert, H. Individualisierte Therapie der Osteoporose. Internist 57, 638–645 (2016). https://doi.org/10.1007/s00108-016-0074-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-016-0074-2

Schlüsselwörter

Keywords

Search

Navigation